Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Keros Therapeutics ( (KROS) ) has issued an update.
On July 9, 2025, Keros Therapeutics announced the resignation of their Chief Medical Officer, Dr. Yung H. Chyung, effective August 1, 2025. Dr. Chyung’s departure is voluntary and not due to any disagreement with the company. Keros has begun the search for a new Chief Medical Officer, acknowledging Dr. Chyung’s contributions to the company.
The most recent analyst rating on (KROS) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Keros Therapeutics stock, see the KROS Stock Forecast page.
Spark’s Take on KROS Stock
According to Spark, TipRanks’ AI Analyst, KROS is a Neutral.
The overall score reflects significant challenges in profitability and strategic direction, as evidenced by the workforce reduction and halted drug project. Technical indicators show neutral momentum, while the financial performance is under pressure despite a strong balance sheet.
To see Spark’s full report on KROS stock, click here.
More about Keros Therapeutics
Keros Therapeutics operates in the biopharmaceutical industry, focusing on developing and commercializing novel therapeutics for the treatment of hematological and musculoskeletal disorders.
Average Trading Volume: 718,725
Technical Sentiment Signal: Sell
Current Market Cap: $586.5M
For a thorough assessment of KROS stock, go to TipRanks’ Stock Analysis page.